Bioinformatics analysis of SRSF1‑controlled gene networks in colorectal cancer

Sheng,Junxiu; Zhao,Jinyao; Xu,Qiuhong; Wang,Linlin; Zhang,Wenjing; Zhang,Yang

doi:10.3892/ol.2017.6900

Bioinformatics analysis of SRSF1‑controlled gene networks in colorectal cancer

Authors:
- Junxiu Sheng
- Jinyao Zhao
- Qiuhong Xu
- Linlin Wang
- Wenjing Zhang
- Yang Zhang
View Affiliations

Affiliations: Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China, Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, Liaoning 116044, P.R. China
Published online on: September 6, 2017 https://doi.org/10.3892/ol.2017.6900
Pages: 5393-5399
Copyright: © Sheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer is the third most common type of cancer and the fourth leading cause of cancer‑associated mortality worldwide. Serine/arginine‑rich splicing factor 1 (SRSF1) is a well‑characterized oncogenic factor that promotes tumorigenesis by controlling a number of alternative splicing events. However, there is limited network analysis, from a global aspect, to study the effect of SRSF1 on colorectal cancer. In the present study, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of available gene regulation data from The Cancer Genome Atlas database revealed the enriched functions and signaling pathways of SRSF1. Subsequently, Oncomine analysis was performed, which demonstrated that SRSF1 was upregulated in a number of types of colon cancer. From overlapping the analysis of 2,678 SRSF1‑related genes and 3,625 colorectal cancer genes in GeneCards, 468 genes were identified as SRSF1‑related colorectal cancer genes. The GO results revealed that these overlapped genes were primarily enriched in metabolic processes, response to DNA damage, regulation of the cell cycle and a number of additional biological processes. KEGG pathway analysis revealed that SRSF1‑related colorectal cancer genes were associated with the cell cycle, deregulated signaling pathways associated with cancer progression and colorectal cancer signaling pathways. In addition, the Search Tool for the Retrieval of Interacting Genes/Proteins database and Cytoscape analysis demonstrated that 468 SRSF1‑related colorectal cancer genes exhibit potential interaction networks in which these genes were enriched in DNA metabolic processes, cell cycle regulation and regulation of apoptosis. The results of the present study suggested that SRSF1 exhibited an increased degree of interaction with key molecules, including NUF2 NDC80 kinetochore complex component, kinesin family member 2C, structural maintenance of chromosomes 3, ATM serine/threonine kinase, BRCA1 DNA repair associated, protein kinase DNA‑activated catalytic polypeptide, heat shock protein 90 alpha family class A member 1, ras homolog family member A, and phosphatase and tensin homolog. Collectively, the bioinformatics analysis of the present study indicated that SRSF1 may have key functions in the progression and development of colorectal cancer.

View Figures

View References

1	Sun Q, Mayeda A, Hampson RK, Krainer AR and Rottman FM: General splicing factor SF2/ASF promotes alternative splicing by binding to an exonic splicing enhancer. Genes Dev. 7:2598–2608. 1993. View Article : Google Scholar : PubMed/NCBI
2	Lemaire R, Prasad J, Kashima T, Gustafson J, Manley JL and Lafyatis R: Stability of a PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: A novel function for SR proteins. Genes Dev. 16:594–607. 2002. View Article : Google Scholar : PubMed/NCBI
3	Huang Y, Gattoni R, Stevenin J and Steitz JA: SR splicing factors serve as adapter proteins for TAP-dependent mRNA export. Mol Cell. 11:837–843. 2003. View Article : Google Scholar : PubMed/NCBI
4	Zhang Z and Krainer AR: Involvement of SR proteins in mRNA surveillance. Mol Cell. 16:597–607. 2004. View Article : Google Scholar : PubMed/NCBI
5	Michlewski G, Sanford JR and Cáceres JF: The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol Cell. 30:179–189. 2008. View Article : Google Scholar : PubMed/NCBI
6	Sun S, Zhang Z, Sinha R, Karni R and Krainer AR: SF2/ASF autoregulation involves multiple layers of post-transcriptional and translational control. Nat Struct Mol Biol. 17:306–312. 2010. View Article : Google Scholar : PubMed/NCBI
7	Sanford JR, Gray NK, Beckmann K and Cáceres JF: A novel role for shuttling SR proteins in mRNA translation. Genes Dev. 18:755–768. 2004. View Article : Google Scholar : PubMed/NCBI
8	Wu H, Sun S, Tu K, Gao Y, Xie B, Krainer AR and Zhu J: A splicing-independent function of SF2/ASF in microRNA processing. Mol Cell. 38:67–77. 2010. View Article : Google Scholar : PubMed/NCBI
9	Anczukow O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, Muthuswamy SK and Krainer AR: The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 19:220–228. 2012. View Article : Google Scholar : PubMed/NCBI
10	Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S and Biamonti G: Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell. 20:881–890. 2005. View Article : Google Scholar : PubMed/NCBI
11	Anczuków O, Akerman M, Cléry A, Wu J, Shen C, Shirole NH, Raimer A, Sun S, Jensen MA, Hua Y, et al: SRSF1-regulated alternative splicing in breast cancer. Mol Cell. 60:105–117. 2015. View Article : Google Scholar : PubMed/NCBI
12	Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D and Krainer AR: The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 14:185–193. 2007. View Article : Google Scholar : PubMed/NCBI
13	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
14	Colon Cancer Treatment (PDQ (R)): Health Professional VersionPDQ Cancer Information Summaries. Bethesda (MD): 2002
15	de Miguel FJ, Sharma RD, Pajares MJ, Montuenga LM, Rubio A and Pio R: Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res. 74:1105–1115. 2014. View Article : Google Scholar : PubMed/NCBI
16	Das S, Anczukow O, Akerman M and Krainer AR: Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep. 1:110–117. 2012. View Article : Google Scholar : PubMed/NCBI
17	Gonçalves V, Henriques AF, Pereira JF, Costa Neves A, Moyer MP, Moita LF, Gama-Carvalho M, Matos P and Jordan P: Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells. Rna. 20:474–482. 2014. View Article : Google Scholar : PubMed/NCBI
18	Thorsen K, Mansilla F, Schepeler T, Øster B, Rasmussen MH, Dyrskjøt L, Karni R, Akerman M, Krainer AR, Laurberg S, et al: Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol Cell Proteomics. 10:M110.0029982011. View Article : Google Scholar : PubMed/NCBI
19	Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteom. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
20	He X, Ee PL, Coon JS and Beck WT: Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res. 10:4652–4660. 2004. View Article : Google Scholar : PubMed/NCBI
21	He X, Arslan AD, Pool MD, Ho TT, Darcy KM, Coon JS and Beck WT: Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene. 30:356–365. 2011. View Article : Google Scholar : PubMed/NCBI
22	Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, et al: WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 20:768–780. 2011. View Article : Google Scholar : PubMed/NCBI
23	Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, López-Picazo JM, Torre W, Pio R and Montuenga LM: The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res. 16:4113–4125. 2010. View Article : Google Scholar : PubMed/NCBI
24	Oltean S and Bates DO: Hallmarks of alternative splicing in cancer. Oncogene. 33:5311–5318. 2014. View Article : Google Scholar : PubMed/NCBI
25	Silipo M, Gautrey H and Tyson-Capper A: Deregulation of splicing factors and breast cancer development. J Mol Cell Biol. 7:388–401. 2015. View Article : Google Scholar : PubMed/NCBI
26	McCleland ML, Gardner RD, Kallio MJ, Daum JR, Gorbsky GJ, Burke DJ and Stukenberg PT: The highly conserved Ndc80 complex is required for kinetochore assembly, chromosome congression and spindle checkpoint activity. Genes Dev. 17:101–114. 2003. View Article : Google Scholar : PubMed/NCBI
27	Kobayashi Y, Takano A, Miyagi Y, Tsuchiya E, Sonoda H, Shimizu T, Okabe H, Tani T, Fujiyama Y and Daigo Y: Cell division cycle-associated protein 1 overexpression is essential for the malignant potential of colorectal cancers. Int J Oncol. 44:69–77. 2014. View Article : Google Scholar : PubMed/NCBI
28	Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, Ito T, Tsuchiya E, Kondo S and Nakamura Y: Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res. 66:10339–10348. 2006. View Article : Google Scholar : PubMed/NCBI
29	Numnum TM, Makhija S, Lu B, Wang M, Rivera A, Stoff-Khalili M, Alvarez RD, Zhu ZB and Curiel DT: Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol. 108:34–41. 2008. View Article : Google Scholar : PubMed/NCBI
30	Kaneko N, Miura K, Gu Z, Karasawa H, Ohnuma S, Sasaki H, Tsukamoto N, Yokoyama S, Yamamura A, Nagase H, et al: siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis. Biochem Biophys Res Commun. 390:1235–1240. 2009. View Article : Google Scholar : PubMed/NCBI
31	Sethi G, Pathak HB, Zhang H, Zhou Y, Einarson MB, Vathipadiekal V, Gunewardena S, Birrer MJ and Godwin AK: An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS One. 7:e470862012. View Article : Google Scholar : PubMed/NCBI
32	Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P and Getzenberg RH: Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med. 9:1532011. View Article : Google Scholar : PubMed/NCBI
33	Hu P, Shangguan J and Zhang L: Downregulation of NUF2 inhibits tumor growth and induces apoptosis by regulating lncRNA AF339813. Int J Clin Exp Pathol. 8:2638–2648. 2015.PubMed/NCBI
34	Sanhaji M, Friel CT, Wordeman L, Louwen F and Yuan J: Mitotic centromere-associated kinesin (MCAK): A potential cancer drug target. Oncotarget. 2:935–947. 2011. View Article : Google Scholar : PubMed/NCBI
35	Ishikawa K, Kamohara Y, Tanaka F, Haraguchi N, Mimori K, Inoue H and Mori M: Mitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer. Br J Cancer. 98:1824–1829. 2008. View Article : Google Scholar : PubMed/NCBI
36	Di Domenico EG, Romano E, Del Porto P and Ascenzioni F: Multifunctional role of ATM/Tel1 kinase in genome stability: from the DNA damage response to telomere maintenance. Biomed Res Int. 2014:7874042014. View Article : Google Scholar : PubMed/NCBI
37	Wang J, Wu Q, Zhang LH, Zhao YX and Wu X: The role of RhoA in vulvar squamous cell carcinoma: A carcinogenesis, progression, and target therapy marker. Tumour Biol. 37:2879–2890. 2016. View Article : Google Scholar : PubMed/NCBI
38	Jeong D, Park S, Kim H, Kim CJ, Ahn TS, Bae SB, Kim HJ, Kim TH, Im J, Lee MS, et al: RhoA is associated with invasion and poor prognosis in colorectal cancer. Int J Oncol. 48:714–722. 2016. View Article : Google Scholar : PubMed/NCBI